Advertisement

Topics

Orexo AB ORX Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125

20:08 EDT 9 Aug 2017 | BioPortfolio Reports

Orexo AB ORX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.

Highlights

Orexo AB Orexo is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company's commercial product portfolio consists of Abstral, Edluar and Zubsolv. its pipeline candidates comprise OX51 for procedureinduced pain; OXCLI for respiratory tract diseases; and OXMPI for inflammation. The company uses its proprietary drug delivery technologies in the development of these products. It also carries out the industrialscale production of pharmaceutical products. Orexo has strategic collaborations with various pharmaceutical companies such as Meda, Kyowa Hakko Kirin, Sentynl Therapeutics, ProStrakan, AstraZeneca and Mundipharma for the development and commercialization of its product portfolio. Orexo is headquartered in Uppsala, Sweden.

Orexo AB Key Recent Developments

Jul 11,2017: Orexo Interim Report Q2 2017
Apr 20,2017: Orexo: Interim Report Q1 2017
Jan 26,2017: Orexo: Full Year Report 2016
Oct 20,2016: Orexo: Interim Report JanuarySeptember 2016
Jul 12,2016: Orexo: Interim Report JanuaryJune 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Orexo AB ORX Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125

NEXT ARTICLE

More From BioPortfolio on "Orexo AB ORX Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125"

Quick Search
Advertisement
 

Relevant Topics

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...